News Releases

Month Year

Month Year

Feb 5, 2021

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 5, 2021

Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 4, 2021

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

--First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--
Dec 4, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 2, 2020

Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

--First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--
Nov 24, 2020

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 13, 2020

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Nov 6, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2020

Insmed to Present at Two November Conferences
Oct 29, 2020

Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation